FDA grants Fast Track designation to Calibr's 'switchable' CAR-T cell cancer therapy

(Scripps Research Institute) The US Food and Drug Administration has granted Fast Track designation to a novel 'switchable' CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process. The therapy is currently being evaluated as a treatment for B-cell malignancies, a class of blood cancers that includes non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news